Exhibit 99.1 Cryoport Reports Second Quarter 2024 Financial Results § Revenue improved sequentially across all businesses § Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially § A record total of 684 global clinical trials supported as of June 30, 2024 § Cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to positive Adjusted EBITDA in 2025 § ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------|----------|--------------------|--------|----------|-------|---------------------------|------------------|----------| | | | | | | | | | | | | June 30, | Three Months Ended | | | | Six Months Ended June 30, | | | | (in thousands) | 2024 | | 2023 | % Change | 2024 | | 2023 | % Change | | Life Sciences Services | | $ 38,040$ 35,204 | | 8 % | | | $ 74,826$ 71,040 | 5 % | | BioLogistics Solutions | 34,517 | | 32,003 | 8 % | | 67,7 ...

Core Viewpoint - Cryoport, Inc. has authorized a $200 million repurchase program for common stock and/or convertible senior notes, aimed at strengthening its balance sheet and maintaining liquidity for long-term growth [1][3]. Group 1: Repurchase Program Details - The 2024 Repurchase Program is effective from August 1, 2024, and will remain in effect until December 31, 2027 [1]. - The company plans to repurchase approximately $160 million of its 0.75% Convertible Senior Notes due in 2026 at an 11.5% discount to par value, resulting in a total repurchase price of $141.6 million plus accrued interest [1][2]. - Following the repurchase, the principal balance of the 2026 Notes will be reduced to approximately $186.2 million from an initial balance of $402.5 million [3]. Group 2: Company Overview - Cryoport, Inc. is a global leader in supply chain solutions for the life sciences, focusing on cell and gene therapies [5]. - The company provides a wide range of supply chain solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, biostorage, and cryogenic systems [5]. - Cryoport operates from its headquarters in Nashville, Tennessee, with over 50 global locations across 17 countries [6].

NASHVILLE, Tenn., July 23, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2024 on Tuesday, August 6, 2024 after U.S. markets close. Conference Call Information Date: Tuesday, August 6, 2024 Time: 5:00 p.m. ET Dial-in numbers: 1-800-717-1738 (U.S.), 1-646-307-1865 (International) Confirmation code:Request the " ...

CryoPort expects revenues to improve as the year goes on. Revenues from the company's Life Sciences Products group are likely to drive growth. Moreover, it seems that investors are bullish on the fact that the Schall Law Firm, a national shareholder rights litigation firm, is investigating claims regarding violations of the securities laws by CYRX. This development might have led to the northward movement of the CYRX stock following losses over the past few weeks. The stock currently carries a Zacks Rank #2 ...

Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnershi ...

Core Viewpoint - The Schall Law Firm is investigating Cryoport, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements or failed to disclose important information to investors [1]. Group 1 - The investigation is aimed at protecting the rights of investors who may have suffered losses due to the company's actions [1]. - Shareholders are encouraged to participate in the investigation if they have experienced financial losses [1]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [2].

Cryoport, Inc. (NASDAQ:CYRX) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – Chief Scientific Officer Robert Stefanovich – Chief Financial Officer Thomas Heinzen – Vice President-Corporate Development and Investor Relations Conference Call Participants Matt Stanton – Jefferies Philip Song – Leerink Partners Lucas Baranowski – UBS David Larsen – BTIG Paul Knight ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (St ...

®2024 CRYOPORT, INC. Condensed Consolidated Statements of Operations (unaudited) | 16 March 31, $ (18,895) $ 46 | 17 Cryoport Enabling the Future of Medicine Increased by 21 trials (net) over Q1 2023 | --- | --- | --- | --- | --- | --- | --- | --- | |---------|-----------|-----------|-----------|-----------|-----------|-----------|-----------| | 350 | 609 | 652 | 675 | 600 | 609 | 652 | 675 | | 300 | | | | 500 | | | | | 250 | | | | 400 | | | | | 200 | | | | 300 | | | | | 150 | | | | 200 | | | | | 100 | | | ...